Novo Nordisk Faces Setback in Kidney Disease Drug Trial
A key drug trial by Novo Nordisk did not meet its main goal, impacting hopes for a new treatment.
Novo Nordisk recently faced a challenge in its work on a new kidney disease medicine. A main study, called a Phase 3 trial, did not work as planned. This drug, ziltivekimab, aimed to help patients with chronic kidney disease (CKD).
Experts believed this medicine could earn a lot of money and help Novo Nordisk offer more types of drugs. The trial's results mean the company needs to re-evaluate its plans for this specific drug.
However, Novo Nordisk has not given up. They have two other studies still going on. These studies are named Artemis and Hermes. The company hopes these ongoing trials might still show good results for the drug. These new trials could help save the program.
Investors and patients are watching to see what happens next. Success in the Artemis and Hermes trials would be a big win. It could bring a new option for people living with chronic kidney disease.
Source: FierceBiotech
More from Biotech
